Lataa...
Targeting CLL-1 for acute myeloid leukemia therapy
Despite major scientific discoveries and novel therapies over the past four decades, the treatment outcomes of acute myeloid leukemia (AML), especially in the adult patient population remain dismal. In the past few years, an increasing number of targets such as CD33, CD123, CLL-1, CD47, CD70, and TI...
Tallennettuna:
| Julkaisussa: | J Hematol Oncol |
|---|---|
| Päätekijät: | , , , |
| Aineistotyyppi: | Artigo |
| Kieli: | Inglês |
| Julkaistu: |
BioMed Central
2019
|
| Aiheet: | |
| Linkit: | https://ncbi.nlm.nih.gov/pmc/articles/PMC6480870/ https://ncbi.nlm.nih.gov/pubmed/31014360 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1186/s13045-019-0726-5 |
| Tagit: |
Lisää tagi
Ei tageja, Lisää ensimmäinen tagi!
|